Atlas Trials

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Clinical trial NCT04728321 · COMPLETED

Trial details

NCT number
NCT04728321
Sponsor
Akeso
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2021-01-27
Primary completion
2022-08-02
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.